MedTrace Logo

Autologous Cell-derived Tissue Engineered Cartilage for Repairing Articular Cartilage Lesions

NCT02770209 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-05-12

No results posted yet for this study

Summary

This study is aimed at evaluating the feasibility and effectiveness of a completely natural tissue engineered cartilage, composed of a self-made tissue engineered oriented scaffold and autologous chondrocytes, for repairing articular cartilage damage following injury. And it is also aimed at investigating the safety of tissue engineered cartilage transplantation.

Conditions

  • Cartilage Diseases

Interventions

BIOLOGICAL

biomimetic cartilage matrix + autologous chondrocytes

PROCEDURE

arthroscopic debridement

PROCEDURE

microfracture surgery

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Quanyi Guo, Ph.D · Institute of Orthopedics, Chinese PLA Hospital, Beijing, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-08-31
Completion
2016-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02770209 on ClinicalTrials.gov